Fuse Oncology Inc, a healthcare technology company focused on radiation oncology, announced on Monday that it has formed a strategic collaboration with Associated Medical Professionals of NY (AMP), an affiliate of U.S. Urology Partners, a General Atlantic company.
Under this collaboration AMP will run a proof of concept of FuseRx, a clinical workflow platform for radiation oncology, at its Center of Advanced Radiation Excellence in Syracuse.
Many large independent urology groups, including AMP, have brought radiation oncology in-house so that a patient is diagnosed, counselled and treated by one team. However, the workflow behind that care still runs across separate systems.
According to Fuse Oncology, FuseRx is built to take a patient from consult to treatment with the physician, physicist, dosimetrist, therapist and nurse working from one plan. The proof of concept at AMP starts with the physician's consult workflow -- the consult note and treatment intent, with the applicable ACRO pathway at the point of decision -- and will extend to the other roles as the full workflow rolls out over the coming months. FuseRx works with the EMR and oncology information system a practice already has.
UChicago Medicine completes construction phase of new cancer facility
FDA Advisory Committee votes in favour of GRAIL's Galleri multi-cancer early detection test
Astellas doses first patient in Phase 3 lung cancer study
X-Chem and Relay Therapeutics collaborate on Phase 3 milestone
BoomRay enters exclusive radioligand therapy asset global license agreement with Novartis
AbbVie and Iambic agree collaboration for discovery and development of small molecule therapies
Grunenthal to acquire Stivarga cancer treatment
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS
Coiled Therapeutics completes enrolment in two AO-252 formulation cohorts
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer